1-11 of 11
Authors: Lisa A Beck
Journal Article
686 - Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.060, https://doi.org/10.1093/bjd/ljae266.060
Published: 08 August 2024
Journal Article
695 - Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.069, https://doi.org/10.1093/bjd/ljae266.069
Published: 08 August 2024
Journal Article
630 - Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.014, https://doi.org/10.1093/bjd/ljae266.014
Published: 08 August 2024
Journal Article
507 - Dupilumab demonstrates greater improvement in disease activity than standard-of-care H1-antihistamines in CSU Get access
British Journal of Dermatology, Volume 190, Issue Supplement_2, February 2024, Page ii12, https://doi.org/10.1093/bjd/ljad498.015
Published: 07 February 2024
Journal Article
417 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years Get access
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.037, https://doi.org/10.1093/bjd/ljad162.037
Published: 20 June 2023
Journal Article
382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab Get access
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.010, https://doi.org/10.1093/bjd/ljad162.010
Published: 20 June 2023
Journal Article
416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years Get access
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.036, https://doi.org/10.1093/bjd/ljad162.036
Published: 20 June 2023
Journal Article
414 Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis Get access
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.034, https://doi.org/10.1093/bjd/ljad162.034
Published: 20 June 2023
Journal Article
438 Potentially greater efficacy with CBP-201 for adults with severe vs. moderate atopic dermatitis at baseline: subgroup analyses from the WW001 phase 2 randomized trial Get access
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.058, https://doi.org/10.1093/bjd/ljad162.058
Published: 20 June 2023
Journal Article
323 Onset of atopic comorbidities relative to atopic dermatitis diagnosis in a real-world setting using an Israeli claims database Get access
British Journal of Dermatology, Volume 188, Issue Supplement_2, February 2023, ljac140.019, https://doi.org/10.1093/bjd/ljac140.019
Published: 25 January 2023
Journal Article
326 Dupilumab: a comparison of infection rates across atopic dermatitis trials in adults, adolescents, children and infants Get access
British Journal of Dermatology, Volume 188, Issue Supplement_2, February 2023, ljac140.021, https://doi.org/10.1093/bjd/ljac140.021
Published: 25 January 2023
